Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2014

01-06-2014

Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach

Auteurs: Adin-Cristian Andrei, Kathleen L. Grady

Gepubliceerd in: Quality of Life Research | Uitgave 5/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.

Methods

To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as quality-adjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT- and PHYS-adjusted OS.

Results

In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT- and PHYS-adjusted OS compared to the placebo arm.

Conclusions

We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Spilker, B. (1996). Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Lippincott Williams & Williams. Spilker, B. (1996). Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Lippincott Williams & Williams.
2.
go back to reference Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2000) . SF-36 health survey: Manual and interpretation guide. Quality Metric Inc. Boston: Health Institute, New England Medical Center, 1993. Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2000) . SF-36 health survey: Manual and interpretation guide. Quality Metric Inc. Boston: Health Institute, New England Medical Center, 1993.
3.
go back to reference Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 25(18S), 5049. Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 25(18S), 5049.
4.
go back to reference Kaarlola, A., Tallgren, M., & Pettil, V. (2006). Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Critical Care Medicine, 34(8), 2120–2126.PubMedCrossRef Kaarlola, A., Tallgren, M., & Pettil, V. (2006). Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Critical Care Medicine, 34(8), 2120–2126.PubMedCrossRef
5.
go back to reference Muennig, P. A., & Gold, M. R. (2001). Using the years-of-healthy-life measure to calculate QALYs. American Journal of Preventive Medicine, 20(1), 35–39.PubMedCrossRef Muennig, P. A., & Gold, M. R. (2001). Using the years-of-healthy-life measure to calculate QALYs. American Journal of Preventive Medicine, 20(1), 35–39.PubMedCrossRef
6.
go back to reference Sindelar, J. L., & Jofre-Bonet, M. (2004). Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal of Behavioral Health Services and Research, 31(3), 229–241.PubMedCrossRef Sindelar, J. L., & Jofre-Bonet, M. (2004). Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal of Behavioral Health Services and Research, 31(3), 229–241.PubMedCrossRef
7.
go back to reference Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., et al. (1998). A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. The New England Journal of Medicine, 339, 1810–1816.PubMedCrossRef Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., et al. (1998). A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. The New England Journal of Medicine, 339, 1810–1816.PubMedCrossRef
8.
go back to reference Rector, T. S., Kubo, S. H., & Cohn, J. H. (1993). Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. American Journal of Cardiology, 71, 1106–1107.PubMedCrossRef Rector, T. S., Kubo, S. H., & Cohn, J. H. (1993). Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. American Journal of Cardiology, 71, 1106–1107.PubMedCrossRef
9.
go back to reference Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment, 5, 559–575.CrossRef Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment, 5, 559–575.CrossRef
10.
go back to reference Glasziou, P. P., Cole, B. F., Gelber, R. D., Hilden, J., & Simes, R. J. (1998). Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine, 17, 1215–1229.PubMedCrossRef Glasziou, P. P., Cole, B. F., Gelber, R. D., Hilden, J., & Simes, R. J. (1998). Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine, 17, 1215–1229.PubMedCrossRef
11.
go back to reference Goldhirsch, A., Gelber, R., Simes, R., Glasziou, P., & Coates, A. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7, 36–44.PubMed Goldhirsch, A., Gelber, R., Simes, R., Glasziou, P., & Coates, A. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7, 36–44.PubMed
12.
go back to reference Glasziou, P. P., Simes, R. J., Gelber, & R. D. (1990). Quality adjusted survival analysis. Statistics in Medicine, 9, 1259–1276.PubMedCrossRef Glasziou, P. P., Simes, R. J., Gelber, & R. D. (1990). Quality adjusted survival analysis. Statistics in Medicine, 9, 1259–1276.PubMedCrossRef
13.
go back to reference Gelber, R. D., Cole, B. F., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. American Statistician, 49, 161–169. Gelber, R. D., Cole, B. F., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. American Statistician, 49, 161–169.
14.
go back to reference Ahlstrom, A., Tallgren, M., Peltonen, S., Rasanen, P., & Pettila, V. (2005). Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Medicine, 31(9), 1222–1228.PubMedCrossRef Ahlstrom, A., Tallgren, M., Peltonen, S., Rasanen, P., & Pettila, V. (2005). Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Medicine, 31(9), 1222–1228.PubMedCrossRef
15.
go back to reference Perkins, M., Howard, V., Wadley, V. G., Crowe, M., Safford, M. M., Haley, W. E., et al. (2013). Caregiving strain and all-cause mortality: evidence from the REGARDS study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 68(4), 504–512.CrossRef Perkins, M., Howard, V., Wadley, V. G., Crowe, M., Safford, M. M., Haley, W. E., et al. (2013). Caregiving strain and all-cause mortality: evidence from the REGARDS study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 68(4), 504–512.CrossRef
16.
go back to reference Nichol, M. B., Sengupta, N., & Globe, D. R. (2001). Evaluating quality-adjusted life years estimation of the Health Utility Index (HUI2) from the SF-36. Medical Decision Making, 21(2), 105–112.PubMedCrossRef Nichol, M. B., Sengupta, N., & Globe, D. R. (2001). Evaluating quality-adjusted life years estimation of the Health Utility Index (HUI2) from the SF-36. Medical Decision Making, 21(2), 105–112.PubMedCrossRef
17.
go back to reference Kamel, H., Johnston, S. C., Easton, J. D., & Kim, A. S. (2012). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke, 43(3), 881–883.PubMedCrossRef Kamel, H., Johnston, S. C., Easton, J. D., & Kim, A. S. (2012). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke, 43(3), 881–883.PubMedCrossRef
18.
go back to reference Rogers, J. G., Bostic, R. R., Tong, K. B., Adamson, R., Russo, M., & Slaughter, M. S. (2012). Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circulation: Heart Failure, 5(1), 10–16. Rogers, J. G., Bostic, R. R., Tong, K. B., Adamson, R., Russo, M., & Slaughter, M. S. (2012). Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circulation: Heart Failure, 5(1), 10–16.
19.
go back to reference Saarni, S., Suvisaari, J., Sintonen, H., Koskinen, S., Harkanen, T., & Lonngvist, J. (2007). The health-related quality of life impact of chronic conditions varied with age in general population. Journal of Clinical Epidemiology, 60(12), 1288–1297.PubMedCrossRef Saarni, S., Suvisaari, J., Sintonen, H., Koskinen, S., Harkanen, T., & Lonngvist, J. (2007). The health-related quality of life impact of chronic conditions varied with age in general population. Journal of Clinical Epidemiology, 60(12), 1288–1297.PubMedCrossRef
20.
go back to reference Ferguson, N. D., Scales, D. C., & Pinto, R., et al. (2013). Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical trials. American Journal of Respiratory and Critical Care Medicine, 187(3), 256–261.PubMedCrossRef Ferguson, N. D., Scales, D. C., & Pinto, R., et al. (2013). Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical trials. American Journal of Respiratory and Critical Care Medicine, 187(3), 256–261.PubMedCrossRef
21.
go back to reference Lin, D. Y., Sun, W., & Ying, Z. (1999). Nonparametric estimation of the gap time distributions for serial events with censored data. Biometrika, 86, 59–70.CrossRef Lin, D. Y., Sun, W., & Ying, Z. (1999). Nonparametric estimation of the gap time distributions for serial events with censored data. Biometrika, 86, 59–70.CrossRef
22.
go back to reference Zhao, H., & Tsiatis, A. A. (1997). A consistent estimator for the distribution of quality adjusted survival time. Biometrika, 84, 339–348.CrossRef Zhao, H., & Tsiatis, A. A. (1997). A consistent estimator for the distribution of quality adjusted survival time. Biometrika, 84, 339–348.CrossRef
23.
go back to reference Gill, R. D. (1983). Large sample behaviour of the product-limit estimator on the whole line. Annals of Statistics, 11, 49–58.CrossRef Gill, R. D. (1983). Large sample behaviour of the product-limit estimator on the whole line. Annals of Statistics, 11, 49–58.CrossRef
24.
go back to reference Andrei, A. -C., & Murray, S. (2006). Estimating the quality-of-life-adjusted gap time distribution of successive events subject to censoring. Biometrika, 93(2), 343–355.CrossRef Andrei, A. -C., & Murray, S. (2006). Estimating the quality-of-life-adjusted gap time distribution of successive events subject to censoring. Biometrika, 93(2), 343–355.CrossRef
Metagegevens
Titel
Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach
Auteurs
Adin-Cristian Andrei
Kathleen L. Grady
Publicatiedatum
01-06-2014
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0608-1

Andere artikelen Uitgave 5/2014

Quality of Life Research 5/2014 Naar de uitgave